文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

成人多系统炎症综合征的临床特征:一项系统评价

Clinical Characteristics of Multisystem Inflammatory Syndrome in Adults: A Systematic Review.
PubMed 文献 · JAMA Netw Open · 2021-09-01
一句话结论成人多系统炎症综合征(MIS-A)多在急性COVID-19后约4周出现发热、低血压和多器官功能障碍,ICU入住率57%、病死率7%。

该系统评价通过文献检索、CDC自愿报告及CDC儿童MIS监测系统中18~20岁者三条途径,纳入221例MIS-A患者。患者中位年龄21岁,70%为男性,58%无基础合并症,68%在发病前中位28天有症状性COVID-19样疾病。最常见表现为发热(96%)、低血压(60%)、心功能障碍(54%)、呼吸困难(52%)和腹泻(52%),中位累及5个器官系统,57%入住ICU,47%需呼吸支持,7%死亡。作者认为MIS-A是急性COVID-19后约4周出现的严重高炎症状态,伴肺外多器官功能障碍。

要点

  • MIS-A患者中位年龄21岁(IQR 19-34),70%(154/219)为男性,58%(122/209)无基础合并症。
  • 68%(102/149)在发病前中位28天(IQR 20-36)有症状性COVID-19样疾病,提示急性感染后约4周出现。
  • 最常见表现为发热96%(197/205)、低血压60%(133/220)、心功能障碍54%(114/210)、呼吸困难52%(102/198)、腹泻52%(102/197)。
  • 中位累及5个器官系统(IQR 4-6),57%(115/201)入住ICU,47%(101/213)需呼吸支持,7%(15/220)死亡。
  • 90%(176/195)有凝血和/或炎症标志物升高,72%(139/194)SARS-CoV-2血清学阳性;10例以川崎病表现就诊。

适用人群与场景

  • 文献检索(2020年5月1日至2021年5月25日)、CDC自愿报告及CDC儿童MIS监测系统中18~20岁者中识别的MIS-A患者,共221例。
  • MIS-A定义为急性COVID-19后出现肺外多器官功能障碍的高炎症状态,具体诊断标准原文未给出。

红旗征与不能漏的情况

  • 发热(96%)、低血压(60%)、心功能障碍(54%)、呼吸困难(52%)、腹泻(52%)为常见就诊表现,需警惕MIS-A。
  • 90%患者有凝血和/或炎症标志物升高,72%SARS-CoV-2血清学阳性,提示需评估高炎症及凝血异常。
  • 10例患者以川崎病表现就诊。

研究设计与关键结果

  • 系统评价共纳入221例MIS-A患者,中位年龄21岁(IQR 19-34),70%(154/219)为男性,36%(60/169)为非西班牙裔黑人,58%(122/209)无基础合并症。
  • 68%(102/149)在发病前中位28天(IQR 20-36)有症状性COVID-19样疾病。
  • 就诊表现:发热96%(197/205)、低血压60%(133/220)、心功能障碍54%(114/210)、呼吸困难52%(102/198)、腹泻52%(102/197);中位累及器官系统数5(IQR 4-6)。
  • 中位住院8天(IQR 5-12);57%(115/201)入住ICU,47%(101/213)需呼吸支持,7%(15/220)死亡。
  • 90%(176/195)有凝血和/或炎症标志物升高,72%(139/194)SARS-CoV-2血清学阳性;10例以川崎病表现就诊。

证据类型、等级与局限

  • 证据类型:系统评价。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为MIS-A是急性COVID-19后约4周出现的严重高炎症状态,伴肺外多器官功能障碍,改进诊断和治疗可能降低COVID-19的发病率和死亡率。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Multisystem inflammatory syndrome in adults (MIS-A) has not been well described. Improved diagnosis and treatment of MIS-A might mitigate COVID-19 morbidity and mortality.

OBJECTIVE: To summarize the descriptive epidemiology and clinical characteristics of MIS-A.

EVIDENCE REVIEW: This systematic review identified patients with MIS-A using 3 strategies: (1) literature review from May 1, 2020, to May 25, 2021, by searching MEDLINE, Embase, Global Health, CAB Abstracts, PsycINFO, CINAHL (Cumulative Index to Nursing and Allied Health Literature), Academic Search Complete, Scopus, World Health Organization Global COVID-19 Literature Database, and Google Scholar; (2) voluntary reports of MIS-A to the Centers for Disease Control and Prevention (CDC); and (3) reports among persons aged 18 to 20 years in the CDC surveillance system for MIS in children.

FINDINGS: Of 221 patients with MIS-A, the median age was 21 (interquartile range [IQR], 19-34) years, and 154 of 219 (70%) with data available were men. Sixty of 169 patients (36%) were non-Hispanic Black individuals, and 122 of 209 (58%) had no underlying comorbidity. One hundred two of 149 patients (68%) noted a previous symptomatic COVID-19-like illness (median, 28 [IQR, 20-36] days previously). Most patients with MIS-A presented with fever (197 of 205 [96%]), hypotension (133 of 220 [60%]), cardiac dysfunction (114 of 210 [54%]), shortness of breath (102 of 198 [52%]), and/or diarrhea (102 of 197 [52%]). The median number of organ systems involved was 5 (IQR, 4-6). Median hospital stay was 8 (IQR, 5-12) days; 115 of 201 patients (57%) were admitted to the intensive care unit; 101 of 213 (47%) required respiratory support, and 15 of 220 (7%) died. Most patients (176 of 195 [90%]) had elevated markers of coagulopathy and/or inflammation and a positive SARS-CoV-2 serologic finding (139 of 194 [72%]). Ten patients with MIS-A presented with Kawasaki disease.

CONCLUSIONS AND RELEVANCE: These findings suggest that MIS-A is a serious hyperinflammatory condition that presents approximately 4 weeks after onset of acute COVID-19 with extrapulmonary multiorgan dysfunction.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Patel P, DeCuir J, Abrams J, et al. Clinical Characteristics of Multisystem Inflammatory Syndrome in Adults: A Systematic Review. JAMA Netw Open. 2021. PMID: 34550381. doi:10.1001/jamanetworkopen.2021.26456

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。